No Data
We Think Zhejiang Medicine (SHSE:600216) Is Taking Some Risk With Its Debt
Zhejiang Medicine Gets Supplemental Drug Approval for Low Blood Pressure Treatment
Zhejiang Medicine (600216.SH): tartaric acid hydroxylamine injection passed the generic drug consistency evaluation.
Zhejiang Medicine (600216.SH) announced that it has recently received the approved and issued Drug Supplementary Application Approval Notice for the Injection of Heavy Tartaric Acid Meptazinol Hydrochloride, which approves the consistency evaluation of generic drug quality and efficacy. The Injection of Heavy Tartaric Acid Meptazinol Hydrochloride is mainly used for the prevention and treatment of acute hypotension occurring during spinal canal block anesthesia; it can be used as an auxiliary symptomatic treatment for low blood pressure caused by bleeding, drug allergies, surgical complications, and shock caused by brain trauma or brain tumors; it can also be used for hypotension caused by cardiogenic shock or sepsis.
Zhejiang Medicine's (SHSE:600216) Earnings Are Of Questionable Quality
Zhejiang Medicine's H1 Profit Jumps 16% on Higher Operating Income
Summary of Zhejiang Medicine's 2024 semi-annual report
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past WeekNo Data
No Data
